Porocarcinoma “A Masquerader as Left InfraClavicular mass” A case report with review of literature
Main Article Content
http://orcid.org/0000-0003-1195-9383
Dr. Khathija Hasan
http://orcid.org/0000-0003-3420-2041
Dr. Moath AbdulAziz AlMasoud
Dr. Abdul Rahman Al Ghannam
Dr. Shehla Riaz Ul Hasan
Dr. Hafiz Mansoor Ul Haq
Dr. Yaser Attia
Dr. Ammar Al Sulaiman
Dr. Amith Ibrahim
Dr. Aissa Saidi
Dr. Mohammed AbdulMajeed Alghadeer
Dr. Manar Abubaker Ahmed Bahammam
Dr. Ali AbdulMajeed Alghadeer
Dr. Walaa Essa Al Mubarak
Dr. Abdullah Mohammed Albin AlSheikh
Heba Abdullah Alisaleh
Eman Hussain AlBasrawi
Abstract
Porocarcinoma, dermal duct tumor or malignant eccrine poroma also called malignant hidrocanthoma simplex is an infrequently reported skin malignancy that arises from the terminal ducts of the sweat gland. First described in 1963 by Pinkus & Mehregan. The term eccrine Porocarcinoma was coined by Mishima & Morioka. The reported incidence less than 1 per 100,000 persons years. Although commonly described in the palms and soles of the feet, it is the head neck followed by the lower extremities that are most affected. The etiology is unknown possible causes include radiation therapy, prolonged solar UV exposure and immunosuppression. The presentation is a painless slow growing red or pink nodular or ulcerative growth seen in the elderly males or females. The diagnosis therefore is delayed as it relies on the sum of Clinical, Histopathology and Immunohistological findings. Clinicians worldwide continue to be unfamiliar with this clinical condition. Masquerading as a benign appearing skin lesion they continue to deliberate on a myraid differential diagnosis from Bowen’s disease, amelanotic melanoma, seborrheic keratosis, fibroma, verruca vulgaris, pyogenic granuloma, and squamous cell carcinoma. Once advanced the prognosis of patients with metastatic Porocarcinoma (PC) continues to be grim, with little evidence based medicine on optimal management case reports will continue to highlight literature on this Masquerader.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
[2].Matloub HS, Cunningham MW, Yousif NJ et al. Eccrine porocarcinoma. Ann Plast Surg. 1988; 20:351–5.
[3].Grishkumar H, Kamineni S, Hwang RR et al. Eccrine porocarinoma. Dermatol Surg. 1997; 23:583–4.
[4]. Puttick L, Ince P, Comaish JS. Three cases of eccrine porocarcinoma. Br J Dermatol. 1986; 115:111–6.
[5]. Snow SN, Reizner GT. Eccrine porocarcinoma of the face. J Am Acad Dermatol 1992;27 (2 Pt 2):306-311.
[6].Bardach H. Hidrocanthoma simplex with in situ porocarcinoma. A case suggesting malignant transformation. J Cutan Pathol 1978;5:236-248.
[7].Pernia LR, Guzman-Stein G, Miller HL. Surgical treatment of an aggressive metastasized eccrine poroma. Ann Plast Surg 1993;30:257-259.
[8]. Huet P, Dandurand M, Pignodel C,et al. Metastasizing eccrine porocarcinoma: report of a case and review of the literature. J Am Acad Dermatol. 1996;35:860–864.
[9].Robson A., Greene J., Ansari N.et al. Eccrine porocarcinoma (malignant eccrine poroma): A clinicopathologic study of 69 cases. Am. J. Surg. Pathol. 2001;25:710–720. doi: 10.1097/00000478-200106000-00002.
[10].Prieto-Granada C., Morlote D., Pavlidakey P et al. Poroid adnexal skin tumors with YAP1 fusions exhibit similar histopathologic features: A series of six YAP1 rearranged adnexal skin tumors. J. Cutan. Pathol. 2021;48:1139–1149.
[11].Snow J.T., Georgantzoglou N., Green D.C, et al. Molecular analysis of NUT-positive poromas and porocarcinomas identifies novel break points of YAP1:NUTM1 fusions. J. Cutan. Pathol. 2022;49: 850–858. doi: 10.1111/cup.14265.
[12].Guimerá Martín-Neda F, García Bustínduy M, Noda Cabrera A et al. A rapidly growing eccrine poroma in a pregnant woman. J Am Acad Dermatol. 2004;50:124–126.
[13].Song S.S., Wu Lee W., Hamman M.S, et al. Mohs Micrographic Surgery for Eccrine Porocarcinoma: An Update and Review of the Literature. Dermatol. Surg. 2015;41:301–306.doi: 10.1097/DSS.0000000000000286.
[14].Sawaya JL, Khachemoune A. Poroma: a review of eccrine, apocrine, and malignant forms [published online April 2, 2014]. Int J Dermatol. doi:10.1111/ijd.12448. [PMID:24697501]
[15].Joshy, J.; Mistry, K.; Levell, N.J. et al. Porocarcinoma- A review. Clin. Exp. Dermatol. 2022.
[16].Merilainen, A.S.; Pukkala, E.; Bohling, et al. Malignant eccrine porocarcinoma in Finland during 2007 to 2017. Acta Derm.-Venereol. 2021, 101, adv00363.
[17].Valverde, K.; Senger, C.; Ngan et al. Eccrine porocarcinoma in a child that evolved rapidly from an eccrine poroma Med. Pediatr. Oncol. 2001, 37, 412–414.
[18].LeN.S.; Janik, S.; Liu, D.T.et al Eccrine porocarcinoma of the head and neck: Meta-analysis of 120 cases. Head Neck 2020, 42, 2644–2659.
[19].Salih, A.M.; Kakamad, F.H.; Baba, H.O.et al. Porocarcinoma; presentation and management, a meta-analysis of 453 cases. Ann. Med. Surg. 2017, 20, 74–79.
[20].Fujii K, et al. Eccrine poromatosis associated with polychemotherapy. Acta Derm Venereol. 2012;92:687–690.
[21].Kircik L, Armus S, Kipping H, Pincus SH. Eccrine poroma in an unusual location. Cutis Jou. 1994;54:183–184.
[22].Choi, C.M.; Cho, H.R.; Lew, B.L.et al Eccrine porocarcinoma presenting with unusual clinical manifestations: A case report and review of the literature. Ann. Dermatol. 2011, 23, s79–s83
[23].Goto, K.; Ishikawa, M.; Hamada et al. Comparison of Immunohistochemical Expression of Cytokeratin 19, c-KIT, BerEP4, GATA3, and NUTM1 Between Porocarcinoma and Squamous Cell Carcinoma. Am. J. Dermatopathol. 2021, 43, 781–787.
[24].Belin E., Ezzedine K., Stanislas S et al. Factors in the Surgical Management of Primary Eccrine Porocarcinoma: Prognostic Histological Factors Can Guide the Surgical Procedure. Br. J. Dermatol. 2011;165:985–989. doi: 10.1111/j.1365-2133.2011 .10486.x.
[25]. Kurisu Y, Tsuji M, Yasuda E, Shibayama Y. A case of eccrine porocarcinoma: usefulness of immunostain for s-100 protein in the diagnoses of recurrent and metastatic dedifferentiated lesions. Ann of Dermatol. 2013;25(3):348-351. doi:10.5021 /ad.2013.25.3.348. [PMID:24003279]
[26].Nazemi A., Higgins S., Swift R et al. Eccrine Porocarcinoma: New Insights and a Systematic Review of the Literature. Dermatol. Surg. 2018;44: 1247–1261. doi:10.1097/DSS.00000000000015
[27].Poiares Baptista, A. Tellechea, O.Reis et al. Eccrine porocarcinoma. A review of 24 cases. Ann. Dermatol. Venereol. 1993, 120, 107–115.
[28].Scampa, M.; Merat, R.; Kalbermatten et al. C.M. Head and Neck Porocarcinoma: SEER Analysis of Epidemiology and Survival. J. Clin. Med. 2022, 11, 2185.
[29].McMeekin TW, Baerg RH, Snyder AJ, et al. Eccrine poroma. Review of the literature and case report. J Am Podiatr Med Assoc 1988;78:43-46.
[30].Shaw M, McKee PH, Lowe D, et al. Malignant eccrine poroma: a study of twenty-seven cases. Br J Dermatol 1982;107:675- 680.
[31].Pembrolizumab (Keytruda) Kwok G, Yau TC, Chiu JW et al. Hum Vaccin Immunother. 2016;12: 2777–2789.
[32].Valverde K, Senger C, Ngan BY, Chan HS. Eccrine porocarcinoma in a child that evolved rapidly from an eccrine poroma. Med Pediatr Oncol. 2001 Oct;37(4):412-4. doi: 10.1002/mpo.12 21. PMID: 11568910.